Results 211 to 220 of about 4,891,805 (263)

Huntington's Disease-like Syndrome as a Rare Presentation of CACNA1A-Related Disorder. [PDF]

Mov Disord Clin Pract
Boumis P, Potagas C, Koros C, Constantinides V, Ragazos N, Koniari C, Aristeidou S, Kartanou C, Linardaki E, Tavernarakis N, Anagnostou E, Stefanis L, Papageorgiou S, Karadima G, Koutsis G.   +14 more
europepmc   +1 more source

Design, Synthesis, and Biological Evaluation of Pyrazolyl Thioureas (PTUs) as SIRT1 and SIRT2 Inhibitors

ChemMedChem, Volume 21, Issue 18, 28 September 2026.
Pyrazolyl thioureas were designed and synthesized as sirtuin 1 (SIRT1) and sirtuin 2 (SIRT2) inhibitors. 6a (IC50 (SIRT1) = 5.3 µM; IC50 (SIRT2) = 2.2 µM) and 7f (IC50 (SIRT1) = 12.4 µM; IC50 (SIRT2) = 13.6 µM) showed micromolar inhibition on target enzymes and HepG2‐based assays confirmed a SIRT2‐mediated effect on tubulin acetylation. Docking studies
Matteo Lusardi, Cecilia Astigiano, Deianira Bellitto, Matteo Raineri, Giorgia Guccione, Annalisa Salis, Elena Cichero, Chiara Brullo, Marco Ponassi, Santina Bruzzone, Andrea Spallarossa   +10 more
wiley   +1 more source

Clinical implications of malnutrition in Huntington's disease progression: evidence from a Chinese cohort and Mendelian randomization. [PDF]

Front Nutr
Xia JQ, Cheng YF, Zhang SR, Ma YZ, Fu JJ, Yang TM, Zhang LY, Burgunder JM, Shang HF.   +8 more
europepmc   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, Volume 65, Issue 39, 21 September 2026.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Decreased Physical Activity as an Early Digital Biomarker in Huntington's Disease: A One-Year Observational Study. [PDF]

Brain Behav
Simón-Vicente L, Calvo S, Mariscal N, Muñoz-Siscart I, Diaz-Piñeiro D, Rivadeneyra J, Cubo E.   +6 more
europepmc   +1 more source

Issue Information

Brain Pathology, Volume 36, Issue 6, November 2026.
wiley   +1 more source

Evaluating the Validity of Model Organisms: A Review and a New Framework for Biologists

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
This article provides an overview on model organisms and proposes a new framework for assessing the extent to which it is justified to generalize the results obtained from a given organism. It covers both studies of human diseases and those focused on general biological processes. The first part of the article is a review on model organisms.
Héloïse Athéa, Nicolas Heck
wiley   +1 more source

SIRT1 in Neurodegenerative Diseases: Molecular Mechanisms, Disease Relevance, and Therapeutic Potential

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
SIRT1, an NAD+‐dependent deacetylase, supports cognitive resilience by coordinating neuroprotection, synaptic plasticity, autophagy–lysosomal proteostasis, and mitochondrial energy homeostasis. Reduced or dysregulated SIRT1 is associated with protein aggregation, neuroinflammation, mitochondrial dysfunction, synaptic loss, and cognitive decline in ...
Jiabin Duan, Jiaqi Liu, Qingsheng Meng, Jiahao Liu, Sitian Yang, Fang Zhou, Jing Cao   +6 more
wiley   +1 more source

The role of oligodendroglial dysfunction in Huntington's disease. [PDF]

J Huntingtons Dis
Li X, Li S, Li XJ, Nguyen HP, Petersen A, Pouladi MA.   +5 more
europepmc   +1 more source